Immix Biopharma to Launch Underwritten Public Offering [MarketWatch]
Immix Biopharma, Inc. (IMMX)
Company Research
Source: MarketWatch
The clinical-stage biopharmaceutical company on Monday said it intends to use the net proceeds from the proposed offering for its working capital and general corporate purposes, as well as for its NXC-201 clinical trials. Advertisement The NXC-201 clinical trials are aimed at treating relapsed/refractory AL amyloidosis, a rare disease that results in protein misfolding and subsequent organ damage. Immix Biopharma didn't disclose how many shares it would offer, or the price of each share. Write to Sabela Ojea at sabela.ojea@wsj.com
Show less
Read more
Impact Snapshot
Event Time:
IMMX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMMX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMMX alerts
High impacting Immix Biopharma, Inc. news events
Weekly update
A roundup of the hottest topics
IMMX
News
- Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma [Yahoo! Finance]Yahoo! Finance
- Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple MyelomaGlobeNewswire
- Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States [Yahoo! Finance]Yahoo! Finance
- Immix Biopharma on Track to Dose NXC-201 Patients in United StatesGlobeNewswire
- Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)GlobeNewswire
IMMX
Sec Filings
- 4/30/24 - Form ARS
- 4/29/24 - Form DEF
- 3/29/24 - Form 10-K
- IMMX's page on the SEC website